Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 81,405,224
  • Shares Outstanding, K 1,632,676
  • Annual Sales, $ 22,561 M
  • Annual Income, $ 4,920 M
  • 60-Month Beta 0.81
  • Price/Sales 3.62
  • Price/Cash Flow 11.40
  • Price/Book 5.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 1.14
  • Number of Estimates 1
  • High Estimate 1.14
  • Low Estimate 1.14
  • Prior Year 0.94
  • Growth Rate Est. (year over year) +21.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.79 +2.25%
on 03/14/19
54.38 -8.26%
on 03/05/19
-1.47 (-2.86%)
since 02/19/19
3-Month
44.30 +12.62%
on 01/03/19
54.38 -8.26%
on 03/05/19
-0.50 (-0.99%)
since 12/19/18
52-Week
44.30 +12.62%
on 01/03/19
67.16 -25.71%
on 03/20/18
-16.18 (-24.49%)
since 03/19/18

Most Recent Stories

More News
Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer

Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

AZN : 42.88 (+0.70%)
MRK : 81.87 (+0.64%)
RHHBY : 33.7500 (-0.32%)
BMY : 49.87 (+0.02%)
Starboard Issues Investor Presentation Opposing Bristol-Myers Squibb's Ill-Advised Proposed Acquisition of Celgene

Starboard Value LP (together with its affiliates, "Starboard"), a stockholder of Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company")(NYSE: BMY), today announced that it has issued an investor...

CELGZ : 1.22 (+6.09%)
BMY : 49.87 (+0.02%)
Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene

Bristol-Myers Squibb Company (NYSE: BMY) today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with its previously announced definitive merger...

CELG : 89.04 (+1.19%)
CELGZ : 1.22 (+6.09%)
BMY : 49.87 (+0.02%)
Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).

CELG : 89.04 (+1.19%)
BDSI : 4.94 (+0.61%)
PFE : 42.32 (+1.22%)
BMY : 49.87 (+0.02%)
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million

Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.

AZN : 42.88 (+0.70%)
NVS : 93.18 (+0.01%)
GSK : 40.46 (-0.07%)
BMY : 49.87 (+0.02%)
AUGUSTUS Demonstrates Favorable Safety Results of Eliquis(R) Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention

The Bristol-Myers Squibb-Pfizer Alliance today announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis(R) (apixaban) versus vitamin K antagonists (VKAs) in patients...

PFE : 42.32 (+1.22%)
BMY : 49.87 (+0.02%)
Keloid Treatment Market Outlook, Opportunity by 2024

New York, March 15, 2019: Global is segmented based on the treatments type as, Occlusive Dressing, Compression Therapy, Cryosurgery, Excision, Radiation Therapy, Laser Therapy, Interferon Therapy, Intralesional...

VRX.TO : 30.80 (-3.33%)
GALE : 0.26 (-7.14%)
AVMXY : 2.7700 (+1.84%)
NVS : 93.18 (+0.01%)
SNOA : 0.98 (-3.92%)
GSK : 40.46 (-0.07%)
BMY : 49.87 (+0.02%)
PRGO : 49.40 (+1.50%)
Infinity Inks Deal With Roche for Phase II Study of IPI-549

Shares of Infinity (INFI) rise after the company inks deal with Roche to initiate a phase II MARIO-3 study on IPI-549. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity.

RCUS : 11.75 (-0.09%)
INFI : 1.80 (unch)
RHHBY : 33.7500 (-0.32%)
BMY : 49.87 (+0.02%)
Merck's Keytruda Gets EU Approval for Difficult Lung Cancer

Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.

BAYRY : 19.7000 (+2.66%)
AZN : 42.88 (+0.70%)
MRK : 81.87 (+0.64%)
BMY : 49.87 (+0.02%)
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others

Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.

MRK : 81.87 (+0.64%)
JNJ : 138.46 (+0.94%)
LLY : 126.49 (+1.00%)
AGN : 154.30 (+2.29%)
RHHBY : 33.7500 (-0.32%)
PFE : 42.32 (+1.22%)
BMY : 49.87 (+0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade BMY with:

Business Summary

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious...

See More

Key Turning Points

2nd Resistance Point 50.35
1st Resistance Point 50.10
Last Price 49.87
1st Support Level 49.62
2nd Support Level 49.39

See More

52-Week High 67.16
Fibonacci 61.8% 58.43
Fibonacci 50% 55.73
Fibonacci 38.2% 53.03
Last Price 49.87
52-Week Low 44.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar